Deprenyl Research Ltd. deal

Goldfarb Corp. and Novopharm Ltd. offered to acquire 20 percent of DEPLF through the purchase of about 4 million treasury shares, at a price not to exceed C$2.75 per share, according to DEPLF. Goldfarb and Novopharm also would purchase warrants for C$0.25 to acquire an additional 19.3 percent.

DEPLF said it is giving "serious consideration" to the offer, which would install Martin Goldfarb as chairman, with current chairman Geoffrey Shulman becoming a director and advisor to the president. Shulman and Martin Barkin, DEPLF president and CEO, also would acquire treasury securities, not to exceed about 10 percent of the company's shares outstanding. DEPLF has 18 million shares outstanding. ...